[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360364-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360364-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","exosomal-lncrna-silc1-from-bicalutamide-activated-mesenchymal-stem-cells-promotes-prostate-cancer-survival-and-bicalutamide-resistance-via-the-mir-577rhoa-axis","Exosomal lncRNA SILC1 from bicalutamide-activated mesenchymal stem cells promotes prostate cancer survival and bicalutamide resistance via the miR-577/RHOA axis","","Resistance to anti-androgen therapies such as bicalutamide poses a major challenge in treating prostate cancer, and the underlying intercellular mechanisms are hard to delineate. Evidence indicates that stem cells and their secreted exosomes contribute to tumor microenvironment-driven drug resistance, yet how these vesicles promote bicalutamide resistance in prostate cancer is unclear. This study clarifies how exosomes from bicalutamide-stimulated mesenchymal stem cells confer bicalutamide resistance in prostate cancer through the lncRNA SILC1 pathway.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exosomal-lncrna-silc1-from-bicalutamide-activated-mesenchymal-stem-cells-promotes-prostate-cancer-survival-and-bicalutamide-resistance-via-the-mir-577rhoa-axis/360364/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exosomal-lncrna-silc1-from-bicalutamide-activated-mesenchymal-stem-cells-promotes-prostate-cancer-survival-and-bicalutamide-resistance-via-the-mir-577rhoa-axis/360364.png","ImageObject",300,407,{"name":42,"@type":43},"Stanford","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main problem addressed by the study?","Question",{"text":63,"@type":64},"The study addresses how prostate cancer develops resistance to bicalutamide and seeks to clarify the role of exosomes in this process.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do the researchers identify the key molecular driver?",{"text":68,"@type":64},"They perform exosomal short RNA sequencing combined with bioinformatics and single-cell data analysis, then validate the downstream network using reporter assays, functional tests, qPCR, and Western blotting.",{"name":70,"@type":61,"acceptedAnswer":71},"What regulatory axis is reported to link exosomal SILC1 to therapy resistance?",{"text":72,"@type":64},"The work proposes an lncRNA SILC1 mechanism that binds miR-577, suppresses it, and thereby promotes RHOA expression, supporting prostate cancer survival and drug resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360364,1790824669,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Yu etal. Journal of Translational Medicine (2026) 24:721  \n[https://doi.org/10.1186/s12967-026-08105-1](https://doi.org/10.1186/s12967-026-08105-1)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nExosomal lncRNA SILC1 from bicalutamide-  activated mesenchymal stem cells promotes prostate cancer survival and bicalutamide resistance via the miR-577/RHOA axis  \nJiayin Yu1†, Haiqi Liang1†, Dingjin Lu1†, Trung Hieu Pham1, Qizhou Mo 1, Mohamud Bashir Hussein1, Jianhua Wen1,4, Qihuan He1, Yujian Li1, Faye Wei1, Guanglin Yang1,2, Xianyong Yan1, Naikai Liao 1, Liwei Wei1, Zelin Cui4, Hao Chen5, Min Qin1*, Fubo Wang1,3* and Jiwen Cheng1,3*  \nAbstract  \nBackground The development of resistance to anti-androgen therapies, such as bicalutamide (Bic), poses a significant challenge in the treatment of prostate cancer (PCa), and the intercellular complex mechanisms are difficult to comprehend. Emerging evidence suggests that stem cells and their secreted exosomes (Exo) contribute to tumor microenvironment-mediated drug resistance. However, the role of these vesicles in promoting bicalutamide resistance in prostate cancer remains elusive. This work aimed to clarify the mechanism by which exosomes from bicalutamide-stimulated mesenchymal stem cells (Bic-MSCs-Exo) provide resistance to bicalutamide in prostate cancer.  \nMethods This work aimed to clarify the function of exosomes produced from Bic-MSCs in bicalutamide resistance in PCa and its molecular underpinnings. The impact of Bic-MSCs supernatants and their exosomes on cell proliferation, clone formation, migratory capacity, and apoptosis was assessed by the co-culturing of these supernatants and exosomes with PCa cells to elucidate their pro-resistance phenotype. Additional short RNA sequencing of exosomes, together with bioinformatics and single-cell data analysis, was conducted to identify and characterize the pivotal molecule lncRNA SILC1 . The downstream regulatory network was validated by dual-luciferase reporter assays, functional rescue and loss-of-function tests, quantitative PCR, and Western blotting; the molecular processes were confirmed at both the in vivo and clinical levels using an organoid model and clinical samples analyzed via FISH.  \n†Co-first authors: Jiayin Yu, Haiqi Liang and Dingjin Lu.  \n*Correspondence: Min Qin [63086204@qq.com](63086204@qq.com)[ ](63086204@qq.com)Fubo Wang [wangfubo@gxmu.edu.cn](wangfubo@gxmu.edu.cn)[ ](wangfubo@gxmu.edu.cn)Jiwen Cheng  \n[chengjiwen@stu.gxmu.edu.cn](chengjiwen@stu.gxmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nYu et al. Journal of Translational Medicine (2026) 24:721 Page 2 of 17  \nResults We found that Bic-MSCs-derived exosomes (Bic-MSCs-Exo) promote prostate cancer (PCa) cell survival and drug resistance. Using sequencing and quantitative PCR (qPCR) an","cbCaihwn9yT2upOR","https://ap.wps.com/l/cbCaihwn9yT2upOR","pdf",15836429,17,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the main problem addressed by the study?\",\"answer\":\"The study addresses how prostate cancer develops resistance to bicalutamide and seeks to clarify the role of exosomes in this process.\"},{\"question\":\"How do the researchers identify the key molecular driver?\",\"answer\":\"They perform exosomal short RNA sequencing combined with bioinformatics and single-cell data analysis, then validate the downstream network using reporter assays, functional tests, qPCR, and Western blotting.\"},{\"question\":\"What regulatory axis is reported to link exosomal SILC1 to therapy resistance?\",\"answer\":\"The work proposes an lncRNA SILC1 mechanism that binds miR-577, suppresses it, and thereby promotes RHOA expression, supporting prostate cancer survival and drug resistance.\"}]","Exosomal lncRNA SILC1 from bicalutamide-activated mesenchymal stem cells promotes prostate cancer survival and bicalutamide resistance via the miR-577/RHOA axis | PDF",1790139791,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6380e09a5e8a2b56ee54d237f9e882a.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84784796e7ea8b2ad7450593d817df3d.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77cbf95becaa87ba10c3366b056b14ed.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3afa78df542f11aa088774c1e6808725.webp",980,1306]